These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 38776229)

  • 81. Frequency analysis of TRBV subfamily sjTRECs to characterize T-cell reconstitution in acute leukemia patients after allogeneic hematopoietic stem cell transplantation.
    Wu X; Zhu K; Du X; Chen S; Yang L; Wu J; Liu Q; Li Y
    J Hematol Oncol; 2011 Apr; 4():19. PubMed ID: 21513557
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Allogeneic hematopoietic stem cell transplantation in adolescent and adult patients with high-risk T cell acute lymphoblastic leukemia.
    Bakr M; Rasheed W; Mohamed SY; Al-Mohareb F; Chaudhri N; Al-Sharif F; Al-Zahrani H; Al-Dawsari G; Saleh AJ; Nassar A; Ahmed S; Elghazaly A; Ahmed SO; Ibrahim K; Chebbo W; El Gohary GM; Al Mahayni MH; Hussain F; Nurgat Z; Elhassan TA; Walter CU; Aljurf M
    Biol Blood Marrow Transplant; 2012 Dec; 18(12):1897-904. PubMed ID: 22824185
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Results from a multicenter, open-label, pivotal phase II study of chidamide in relapsed or refractory peripheral T-cell lymphoma.
    Shi Y; Dong M; Hong X; Zhang W; Feng J; Zhu J; Yu L; Ke X; Huang H; Shen Z; Fan Y; Li W; Zhao X; Qi J; Huang H; Zhou D; Ning Z; Lu X
    Ann Oncol; 2015 Aug; 26(8):1766-71. PubMed ID: 26105599
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Comparison of Outcomes of Allogeneic Hematopoietic Cell Transplantation for Multiple Myeloma Using Three Different Conditioning Regimens.
    Maymani H; Lin P; Saliba RM; Popat U; Bashir Q; Shah N; Patel K; Parmar S; Kebriaei P; Hosing C; Ciurea S; Andersson B; Shpall E; Champlin R; Srour SA; Qazilbash MH
    Biol Blood Marrow Transplant; 2019 May; 25(5):1039-1044. PubMed ID: 30639822
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Impact of Conditioning Regimen on Outcomes for Children with Acute Myeloid Leukemia Undergoing Transplantation in First Complete Remission. An Analysis on Behalf of the Pediatric Disease Working Party of the European Group for Blood and Marrow Transplantation.
    Lucchini G; Labopin M; Beohou E; Dalissier A; Dalle JH; Cornish J; Zecca M; Samarasinghe S; Gibson B; Locatelli F; Bertrand Y; Abdel-Rahman F; Socie G; Sundin M; Lankester A; Sedlacek P; Hamladji RM; Heilmann C; Afanasyev B; Hough R; Peters C; Bader P; Veys P
    Biol Blood Marrow Transplant; 2017 Mar; 23(3):467-474. PubMed ID: 27916512
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Reduced-Intensity Conditioning and Dual T Lymphocyte Suppression with Antithymocyte Globulin and Post-Transplant Cyclophosphamide as Graft-versus-Host Disease Prophylaxis in Haploidentical Hematopoietic Stem Cell Transplants for Hematological Malignancies.
    Law AD; Salas MQ; Lam W; Michelis FV; Thyagu S; Kim DDH; Lipton JH; Kumar R; Messner H; Viswabandya A
    Biol Blood Marrow Transplant; 2018 Nov; 24(11):2259-2264. PubMed ID: 30009980
    [TBL] [Abstract][Full Text] [Related]  

  • 87. A new intensive conditioning regimen for allogeneic hematopoietic stem cell transplantation in patients with refractory or relapsed acute myeloid leukemia.
    Wang J; Zhao J; Fei X; Yin Y; Cheng H; Zhang W; Gu J; Yang F; Yang Y; Xue S; Tian Z; He J; Zhang S; Wang X
    Medicine (Baltimore); 2018 Apr; 97(17):e0228. PubMed ID: 29702970
    [TBL] [Abstract][Full Text] [Related]  

  • 88. [Increased risk of severe acute graft-versus-host disease in low body mass index patients undergoing haploidentical allogeneic stem cell transplantation].
    Chen Y; Xu L; Liu D; Liu K; Chen H; Zhang X; Wang F; Wang J; Wang Y; Han W; Chen Y; Yan C; Zhao T; Huang X
    Zhonghua Nei Ke Za Zhi; 2014 Sep; 53(9):710-4. PubMed ID: 25511404
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Allogeneic hematopoietic cell transplantation using fludarabine plus myeloablative busulfan and melphalan confers promising survival in high-risk hematopoietic neoplasms: a single-center retrospective analysis.
    Edahiro T; Kawase T; Nagoshi H; Fujino K; Toishigawa K; Miyama T; Mino T; Yoshida T; Morioka T; Hirata Y; Noma M; Fujii T; Nishizawa M; Fukushima N; Ichinohe T
    Hematology; 2021 Dec; 26(1):186-198. PubMed ID: 33594942
    [TBL] [Abstract][Full Text] [Related]  

  • 90. The Impact of a Humanized CCR4 Antibody (Mogamulizumab) on Patients with Aggressive-Type Adult T-Cell Leukemia-Lymphoma Treated with Allogeneic Hematopoietic Stem Cell Transplantation.
    Kawano N; Kuriyama T; Yoshida S; Kawano S; Yamano Y; Marutsuka K; Minato S; Yamashita K; Ochiai H; Shimoda K; Ishikawa F; Kikuchi I
    J Clin Exp Hematop; 2017; 56(3):135-144. PubMed ID: 28331127
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Busulfan plus fludarabine as a myeloablative conditioning regimen compared with busulfan plus cyclophosphamide for acute myeloid leukemia in first complete remission undergoing allogeneic hematopoietic stem cell transplantation: a prospective and multicenter study.
    Liu H; Zhai X; Song Z; Sun J; Xiao Y; Nie D; Zhang Y; Huang F; Zhou H; Fan Z; Tu S; Li Y; Guo X; Yu G; Liu Q
    J Hematol Oncol; 2013 Feb; 6():15. PubMed ID: 23394705
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Second allogeneic stem cell transplantation using nonmyeloablative conditioning for patients who relapsed or developed secondary malignancies following autologous transplantation.
    Nagler A; Or R; Naparstek E; Varadi G; Slavin S
    Exp Hematol; 2000 Sep; 28(9):1096-104. PubMed ID: 11008023
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Comparable outcomes of allogeneic peripheral blood versus bone marrow hematopoietic stem cell transplantation from a sibling donor for pediatric patients.
    Kim BK; Hong KT; Choi JY; Kim H; Park HJ; Kang HJ
    Ann Hematol; 2024 Jun; 103(6):2051-2058. PubMed ID: 38594416
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Impact of in vivo T cell depletion in HLA-identical allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission conditioned with a fludarabine iv-busulfan myeloablative regimen: a report from the EBMT Acute Leukemia Working Party.
    Rubio MT; D'Aveni-Piney M; Labopin M; Hamladji RM; Sanz MA; Blaise D; Ozdogu H; Daguindeau E; Richard C; Santarone S; Irrera G; Yakoub-Agha I; Yeshurun M; Diez-Martin JL; Mohty M; Savani BN; Nagler A
    J Hematol Oncol; 2017 Jan; 10(1):31. PubMed ID: 28118857
    [TBL] [Abstract][Full Text] [Related]  

  • 95. The impact of total body irradiation-based regimens on outcomes in children and young adults with acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplantation.
    Friend BD; Bailey-Olson M; Melton A; Shimano KA; Kharbanda S; Higham C; Winestone LE; Huang J; Stieglitz E; Dvorak CC
    Pediatr Blood Cancer; 2020 Feb; 67(2):e28079. PubMed ID: 31724815
    [TBL] [Abstract][Full Text] [Related]  

  • 96. [Effect of BU and CY versus TBI and CY as conditioning regimens on the efficacy of haploidentical stem cell transplantation in patients with hematologic malignancy].
    Shao Q; Han D; Liu D; Zheng X; Dong L; Wang Z; Ding L; Yan H; Wang H; Duan L
    Zhonghua Xue Ye Xue Za Zhi; 2014 Jun; 35(6):505-10. PubMed ID: 24985173
    [TBL] [Abstract][Full Text] [Related]  

  • 97. [Efficacy and Safety of Cladribine-based Intensified Conditioning Regimen in Hematopoietic Stem Cell Transplantation in Patients with High-Risk Acute Myeloid Leukemia].
    Pan WY; Li KX; Wu HY; He YZ; DU JW; Zheng YL; Tu SF; Song CY; Li YH; Huang YX
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Feb; 30(1):65-71. PubMed ID: 35123605
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Calcineurin inhibitor--free graft-versus-host disease prophylaxis with post-transplantation cyclophosphamide and brief-course sirolimus following reduced-intensity peripheral blood stem cell transplantation.
    Solomon SR; Sanacore M; Zhang X; Brown S; Holland K; Morris LE; Bashey A
    Biol Blood Marrow Transplant; 2014 Nov; 20(11):1828-34. PubMed ID: 25064745
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Addition of sirolimus to standard cyclosporine plus mycophenolate mofetil-based graft-versus-host disease prophylaxis for patients after unrelated non-myeloablative haemopoietic stem cell transplantation: a multicentre, randomised, phase 3 trial.
    Sandmaier BM; Kornblit B; Storer BE; Olesen G; Maris MB; Langston AA; Gutman JA; Petersen SL; Chauncey TR; Bethge WA; Pulsipher MA; Woolfrey AE; Mielcarek M; Martin PJ; Appelbaum FR; Flowers MED; Maloney DG; Storb R
    Lancet Haematol; 2019 Aug; 6(8):e409-e418. PubMed ID: 31248843
    [TBL] [Abstract][Full Text] [Related]  

  • 100. The impact of HLA-matching on reduced intensity conditioning regimen unrelated donor allogeneic stem cell transplantation for acute myeloid leukemia in patients above 50 years-a report from the EBMT acute leukemia working party.
    Rubio MT; Savani BN; Labopin M; Polge E; Niederwieser D; Ganser A; Schwerdtfeger R; Ehninger G; Finke J; Renate A; Craddock C; Kröger N; Hallek M; Jindra P; Mohty M; Nagler A
    J Hematol Oncol; 2016 Aug; 9(1):65. PubMed ID: 27488518
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.